Trelegy Ellipta

(Fluticasone furoate, umeclidinium, and vilanterol)

Trelegy Ellipta

Drug updated on 11/17/2023

Dosage FormPowder (inhalation; fluticasone furoate/ umeclidinium/ vilanterol; 100/62.5/25 mcg) Powder (inhalation; fluticasone furoate/ umeclidinium/ vilanterol; 200/62.5/25 mcg)
Drug ClassMultiple
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
  • For the maintenance treatment of asthma in patients aged 18 years and older.

Product Monograph / Prescribing Information

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines